SEARCH

SEARCH BY CITATION

References

  • 1
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212236
  • 2
    Kruck S, Bedke J, Kuczyk MA, Merseburger AS. Second line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2012; 12: 777785
  • 3
    Karakiewicz PI, Suardi N, Capitanio U et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2009; 55: 287295
  • 4
    Bedke J, Buse S, Pritsch M et al. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU Int 2009; 103: 13491354
  • 5
    Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58: 398406
  • 6
    Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol 2009; 181: 10201027
  • 7
    Maxine S, Shahrokh FS, Christopher C et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011; 60: 644661
  • 8
    Kruck S, Merseburger AS, Hennenlotter J et al. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int 2012; 109: 15651570
  • 9
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539545
  • 10
    Kataoka H, Tanaka H, Nagaike K, Uchiyama S, Itoh H. Role of cancer cell–stroma interaction in invasive growth of cancer cells. Hum Cell 2003; 16: 114
  • 11
    Bedke J, Stenzl A. Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol 2010; 7: 339347
  • 12
    Bedke J, Laske K, Feyerabend S et al. 76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur Urol 2012; 11: e76ea
  • 13
    Whiteside T. The role of immune cells in the tumor microenvironment the link between inflammation and cancer. In Dalgleish AG , Haefner B eds, The Link Between Inflammation and Cancer: Wounds That Do Not Heal, Vol. 130. New York: Springer, 2006: 103124
  • 14
    Wu Y, Fu X, Zhu X et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2011; 137: 887896
  • 15
    Gakis G, Todenhofer T, Renninger M et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 2011; 108: 18001805
  • 16
    Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009; 32: 471482
  • 17
    Johnson TV, Abbasi A, Owen-Smith A et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 2010; 76: 766 e1–5
  • 18
    Iimura Y, Saito K, Fujii Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009; 181: 10041012
  • 19
    Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109: 205212
  • 20
    Negrier S, Gomez F, Douillard JY et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol 2005; 23: 161165
  • 21
    Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655663
  • 22
    Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982; 247: 25432546
  • 23
    Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res 2008; 14: 59775983
  • 24
    Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561571
  • 25
    Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011; 8: 659666
  • 26
    Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860867
  • 27
    Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27: 47094717
  • 28
    Karakiewicz PI, Hutterer GC, Trinh QD et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007; 110: 12411247
  • 29
    Jagdev SP, Gregory W, Vasudev NS et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010; 103: 16491656
  • 30
    Takayama T, Sugiyama T, Kai F et al. Characteristics of aggressive variants in T1a renal cell carcinoma. J Cancer Res Clin Oncol 2011; 137: 16531659
  • 31
    Saito K, Tatokoro M, Fujii Y et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009; 55: 11451153
  • 32
    Manola J, Royston P, Elson P et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin Cancer Res 2011; 17: 54435450
  • 33
    Panichi V, Migliori M, De Pietro S et al. C reactive protein in patients with chronic renal diseases. Ren Fail 2001; 23: 551562
  • 34
    Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 8792
  • 35
    Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 2008; 101: 959963
  • 36
    Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 611
  • 37
    Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766772
  • 38
    Karakiewicz PI, Briganti A, Chun FK et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25: 13161322
  • 39
    Walter S, Weinschenk T, Stenzl A et al. Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide. Nat Med 2012; 18: 12541261